Navigation Links
FDA Accords Priority Review For Pediatric Crohn's Disease Drug

The U.S. Food and Drug Administration (FDA) has decided to accord a priority review for the drug REMICADE (R) (infliximab) to be used in the treatment of pediatric// Crohn's disease, the drug's manufacturer Centocor, Inc. announced today. Crohn's disease affects the gastrointestinal tract and causes diarrhea, fever, abdominal pain and weight loss. As of now there is no drug to treat children who develop this condition. Centocor had filed a supplemental Biologics License Application (sBLA), which was accepted by the FDA.

The filing is based primarily on Phase 3 study results showing the unprecedented efficacy of REMICADE in the treatment of children with moderately to severely active Crohn's disease. In the REACH (a Randomized, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Anti-TNF Monoclonal Antibody REMICADE in Pediatric Subjects with Moderate to Severe Crohn's Disease) trial, nearly 90 percent (88.4 percent) of pediatric patients with moderately to severely active Crohn's disease who had an inadequate response to conventional therapy achieved clinical response at week 10 when treated with REMICADE. Nearly two-thirds (63.5 percent) of the patients who were randomized to treatment with REMICADE every 8 weeks were in clinical response at one year. Additionally, more than half of the patients treated with REMICADE every 8 weeks were in clinical remission at the end of one year.

"We are extremely pleased by the results of the REACH trial and by the FDA's decision to accept the application with a Priority Review," said Jerome A. Boscia, MD, Senior Vice President, Clinical Research and Development, Centocor, Inc. "REMICADE, if approved for the treatment of pediatric Crohn's disease, would represent a major advancement for children with this serious condition. We look forward to working closely with the FDA as it reviews these data for approval."

Priority Review is granted by the FDA to products that are considered to be a potential therapeutic advance over current therapies. Acceptance of the sBLA filing does not mean that a license has been issued for this indication nor does it represent any evaluation of the adequacy of the data submitted in the sBLA. REMICADE was FDA-approved in 1998 as the first biologic treatment for adults with moderate to severe Crohn's disease. In September 2005, REMICADE also became the first approved biologic treatment for moderate to severe ulcerative colitis (UC), making it the only biologic indicated for the treatment of both types of inflammatory bowel disease (IBD) in adults. Contact: Michael Parks 215-983-8000 Centocor, Inc. Source: Eurekalert
'"/>




Related medicine news :

1. British MPs Say Prostate Cancer Receives Low Priority in the NHS
2. Funds Pumped In To Reduce Waiting List of Priority Patients
3. Children Health Care To Be Given Priority
4. Hypertension Not Given Priority during Treatment
5. Healthcare And Education Top Most Priority Of The Govt: Nitish
6. Global Health Issues To Take Priority In The Current G8 Summit In Russia
7. Consistent National Standards For Assessment Of Overseas Trained Doctors A Priority
8. Women and Children Issues Should Get Priority in India
9. WHO Urges Higher Priority for Neglected Diseases
10. COAG Must Make Combating Severe Allergies A National Priority
11. Priority Needs to Be Given to Maternal Health in Afghanistan
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/17/2018)... ... August 17, 2018 , ... Tinnitus 911 ... The PhytAge Laboratories supplement company will soon launch their new website, Tinnitus ... globe. The website will highlight opportunities for support. Support opportunities will include ones ...
(Date:8/15/2018)... (PRWEB) , ... August 15, 2018 , ... Today David ... Kickstarter. , Born out of a desire for confidence and comfort ... marks and body odor – even in the hottest, most humid of climates. , ...
(Date:8/15/2018)... ... August 15, 2018 , ... On July 30, more than 250 ... Club and Century Country Club in Westchester County. The event raised over $300,000 for ... and dinner, the event included a performance by mentalist and comedian Eric Dittelman, a ...
(Date:8/14/2018)... ... August 14, 2018 , ... Health & hygiene ranked eighth out ... the largest study of brands based on emotions. In the U.S., Olay again topped ... for the health & hygiene industry were: Listerine, Nivea, Gillette, Colgate, Head & Shoulders, ...
(Date:8/14/2018)... (PRWEB) , ... August 14, 2018 , ... Ross A. ... generation of freezing fat, at Clevens Face and Body Specialists. Dr. Clevens is known ... patients at his Melbourne and Merritt Island offices. Along with his associate, Amy Simon, ...
Breaking Medicine News(10 mins):
(Date:8/7/2018)... CHURCH, Va. (PRWEB) , ... August 07, 2018 , ... ... Aug. 16, 2018 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/commissionergottliebsfda ... Some drug and device makers may have benefited, some may have gotten hurt. , ...
(Date:8/3/2018)... ... August 03, 2018 , ... Flexefits, a pioneer in direct -pay, ... for its allowing participants in Direct Primary Care arrangements to keep HSA eligibility and ... $150 per individual and $300 per family per month.) , “We are very pleased ...
(Date:8/2/2018)... ... ... UMD Professor Utpal Pal leads a team of investigators across multiple institutions ... of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), ... contribute to the spread of major diseases like Lyme disease. Pal is the project ...
Breaking Medicine Technology: